Alan Pehrson, a broadly trained neurobiologist focused on developing novel pharmacological treatments for central nervous system disorders, will deliver a neuroscience colloquium at Northern Michigan University. His presentation is scheduled at 2 p.m. Friday, Dec. 5, in Mead Auditorium in the West Science Building. It is free and open to the public.
Pehrson joined Lundbeck Research USA in 2010 and was a member of the team that discovered a multimodal antidepressant drug, vortioxetine (Brintellix), which was FDA approved in 2013. He will discuss his recent research exploring serotonin and glutamate neurotransmission as a strategy for treating cognitive dysfunction.